Fundraising Fox

Prolacta

City Of Industry, US · Founded 1999 · Delaware corporation · 321 employees on LinkedIn · 5 known investors

Prolacta Bioscience manufactures 100% human milk-based nutritional products and fortifiers for premature and critically ill infants in hospital neonatal intensive care units. The company's products are used to support nutrition and reduce complications in extremely premature infants globally.

BiotechHealthtechMedical Devices

Founders & leadership

SEScott Elster
Scott ElsterExecutive
JMJohn M. Shields
John M. ShieldsExecutive

Board

FF
Frank FosterBoard directorManaging Director at Frontier Venture Capital
MSMartin Sutter
Martin SutterBoard directorFounding Partner at Essex Woodlands Healthcare Partners
DB
David BrailerBoard director
DJDan Janney
Dan JanneyBoard directorManaging Director at Alta Partners
JB
John Bacich, Jr.Board director
ES
Ernie StrapazonBoard director
NB
Ned BrownBoard director
SC
Sally CrawfordBoard director

Investors · 5

Aisling CapitalNew York
Essex Woodlands Healthcare PartnersNew York · $20M – $80M
Frontier Venture CapitalBoulder · $50K – $500K
PROOFArlington
Alta Partnersreported · 2 sourcesJackson · $1M – $12Mvia Dan Janney · board

Reported raises · per SEC filings

Form D private placements

$43.9M disclosed across 2 rounds · 2016–2018

▶$8.9MraisedMay 2018 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • John ShieldsExecutive Officer
  • David BrailerDirector
  • Mark HannonExecutive Officer
  • Victoria NiklasExecutive Officer
  • Ernie StrapazonDirector
  • Frank FosterDirector
  • John Bacich Jr.Director
  • David DreyerExecutive Officer
  • Vincent GasparExecutive Officer
  • Alan KofskyExecutive Officer
  • Martin SutterDirector
  • Scott EakerExecutive Officer
  • Scott ElsterExecutive Officer, Director
  • Joseph FournellExecutive Officer
  • Martin LeeExecutive Officer
  • Dan JanneyDirector
  • Sally CrawfordDirector
  • Alyson FullerExecutive Officer
Offering amount
$8.9M
Amount sold
$8.9M
First sale
May 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$35MraisedDec 2016 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Scott ElsterExecutive Officer, Director
  • Frank FosterDirector
  • Martin SutterDirector
  • John Bacich, Jr.Director
  • Ernie StrapazonDirector
  • Ned BrownDirector
  • Sally CrawfordDirector
  • David BrailerDirector
  • Dan JanneyDirector
  • John M. ShieldsExecutive Officer
Offering amount
$35M
Amount sold
$35M
First sale
Nov 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Mamava400 shared keywordsMamava designs, engineers, and manufactures freestanding lactation pods for workplaces and public spaces, along with breastfeeding resources for employers and organizations and a free app that helps parents locate lactation spaces. Its pods are produced at the company's facility in Springfield, Vermont, and are installed across the United States and beyond.

Companies competing with Prolacta for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

The Prolacta Bioscience Foundation Empowers Parents and Communities With Over Half a Million Dollars in Grant Funding in 2022prnewswire.com · Feb 2023Prolacta Bioscience(R) Raises $35 Million in Mezzanine Financingfinance.yahoo.com · Dec 2016UPDATE - Prolacta Bioscience(R) Raises $35 Million in Mezzanine Financingglobenewswire.com · Dec 2016Prolacta Bioscience Raises Series D funding from Health Evolution Partners - FinSMEsfinsmes.com · Nov 2011Prolacta Raises $12 Million | PE Hubpehub.com · May 2007

Frequently asked questions

What does Prolacta do?
Prolacta Bioscience manufactures 100% human milk-based nutritional products and fortifiers for premature and critically ill infants in hospital neonatal intensive care units. The company's products are used to support nutrition and reduce complications in extremely premature infants globally.
Who are Prolacta's investors?
Prolacta's investors include Aisling Capital, Essex Woodlands Healthcare Partners, Frontier Venture Capital, PROOF, Alta Partners.
How much funding has Prolacta raised?
Prolacta has disclosed $43.9M raised across 2 rounds.
Where is Prolacta headquartered?
Prolacta is headquartered in City Of Industry, US.